Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Paritaprevir→

Paritaprevir Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1216941-48-8
PubChem CID
45110509
Molecular formula
C40H43N7O7S
Molecular weight
765.9 g/mol
Drug class
Hepatitis C virus (HCV) NS3/4A serine protease inhibitordirect-acting antiviral
Mechanism of action
Reversibly binds the active centre of the HCV NS3/4A protease and prevents protease-mediated cleavage of the viral polyprotein, disrupting maturation of viral proteins needed for replication. It is used in combination regimens; ritonavir increases paritaprevir exposure through CYP3A4 inhibition.
Indications / reported uses
  • Used only as part of labelled combination regimens for chronic hepatitis C, such as ombitasvir/paritaprevir/ritonavir with or without dasabuvir; indication and availability are regimen- and jurisdiction-specific.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ombitasvir-paritaprevir-ritonavir · https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax

Identification source: PubChem record (CID 45110509). The linked PubChem record is provided for identity reference. Confirm the exact salt, hydrate, isomer, mixture, or product form against authoritative source documentation when defining the assessment scope.

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Paritaprevir Environmental Risk Assessment (ERA) (the Paritaprevir ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.